Adding niraparib to AAP and ADT improved rPFS in mCSPC patients with HRR mutations in the phase 3 AMPLITUDE trial.

Dr. Alicia Morgans discussed complications associated with ADT in prostate cancer, and how men can still maintain quality of ...